Novartis COX-2 Inhibitor Market Entry Projected For 2003
Executive Summary
Novartis expects to introduce its COX-2 inhibitor COX-189 by 2003.
You may also be interested in...
Celebrex, Vioxx GI Safety Data To Be Reviewed By FDA Committee Feb. 7-8
Applications to modify the NSAID class gastrointestinal safety labeling for the COX-2 inhibitors Celebrex and Vioxx will be reviewed by FDA's Arthritis Advisory Committee Feb. 7-8.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials